1. Home
  2. Programs
  3. NeuroFrontiers

Unraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
  • Overview

    While B-cell follicles in the brain’s meninges were previously suspected to drive cortical lesions in multiple sclerosis (MS), studies show ocrelizumab has little impact on B-cell follicles—yet it still significantly reduces cortical lesions. This suggests that another, yet-to-be-understood B-cell-mediated process may be at play. Tune in to hear Dr. Michael G. Dwyer discuss the potential mechanisms behind ocrelizumab’s effect on cortical lesions in MS patients. Dr. Dwyer is an Associate Professor of Neurology and Biomedical Informatics at the University at Buffalo.

Recommended
Details
Presenters
  • Overview

    While B-cell follicles in the brain’s meninges were previously suspected to drive cortical lesions in multiple sclerosis (MS), studies show ocrelizumab has little impact on B-cell follicles—yet it still significantly reduces cortical lesions. This suggests that another, yet-to-be-understood B-cell-mediated process may be at play. Tune in to hear Dr. Michael G. Dwyer discuss the potential mechanisms behind ocrelizumab’s effect on cortical lesions in MS patients. Dr. Dwyer is an Associate Professor of Neurology and Biomedical Informatics at the University at Buffalo.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free